Wade Iams is an Oncology physician affiliated with Centerstone. OpenAlex indexes 325 publications with 3,973 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3601 The Vanderbilt Clinic
Nashville, TN 37232
Telephone
615-322-3384Provider last certified this registry record 18 Mar 2022.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
34 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Amgen Inc.Program year202576 payments$100,053openpaymentsdata.cms.gov ↗
- JAZZ PHARMACEUTICALS INC.Program year202528 payments$67,808openpaymentsdata.cms.gov ↗
- Novocure Inc.Program year202531 payments$42,961openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
25.6%Corticosteroid25.6%Dexamethasone sodium phosphate87%Dexamethasone8%Hydrocortisone5%Part D + Part B<11 patientsNervous system
25%Benzodiazepine5.9%Clonazepam31%Diazepam29%Alprazolam27%Lorazepam13%Part D<11 patientsGabapentinoids5.7%Gabapentin100%Part D≥28 patients+ 6 more classes in this area
Metabolism & gastrointestinal
20.5%Corticosteroid7.5%Prednisone100%Part D≥30 patientsSerotonin-3 Receptor Antagonist5%Ondansetron Hcl57%Ondansetron Odt43%Part D≥28 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”